Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Scrutinizing the Advancing Research
- Influenza 2018


International Conference on Influenza is going to be held at Orlando, USA during March 28-29, 2018 hosted by Allied Academies through the theme “Scrutinizing the Advancing Research”, conference will explore the Influenza research and various ailments. Influenza 2018 is an excellent opportunity for the delegates from Universities, Welfare organizations, NGO's and Educational Institutions to interact with the world class Scientists.

This two-day meeting will address key issues concerning Influenza strains and its impacts in the broader context of Epidemiology, Pathology, Virology, Parasitology and Immunology. The Conference focuses on moving from present knowledge to future scope and advancements.

Influenza 2018 will attract a large group of scientists and researchers round the globe. The target audience will be from the fields of Epidemiology, Virology, Microbiology, Public Health, NHS, Immunology, Health care sector, Clinicians, Professors, members from Associations and Societies will also share the platform.

Allied Academies

Allied Academies is an international collaborative venture incorporating academicians, researchers, scholars and business entrepreneurs to exchange information from past two decades through international scientific meetings and Journals. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. The conferences provide a global platform for the attendees to showcase their research and services in front of many key players in the field.

We are a globally recognized and trusted organization to provide unique scientific and business services through our Journals and we are expanding the functionality of our International conferences.

Market Analysis

Influenza is a highly communicable disease and typically has the most severe impact on children and the elderly. Influenza viruses are considered as a major cause of morbidity and mortality worldwide. According to World Health Organization (WHO) annually influenza epidemics cause 5-15% of the population with upper respiratory tract infections which needs prompt and accurate diagnosis to effectively manage of influenza epidemics. Growing prevalence of influenza worldwide, government initiatives in awareness and diagnostic programs are driving the growth of influenza diagnostics market globally. For the purpose of study, the influenza diagnostics market is segmented on the basis of test type such as rapid influenza diagnostic tests (RIDT), RT-PCR, cell culture and others. In the base year 2016, rapid influenza diagnostic tests (RIDT) was the major revenue generating segment and is expected to show growth during forecast period; as it considered the gold standard in influenza diagnostics, faster onset of result and ease of use are influencing the growth of rapid influenza diagnostic tests (RIDT) market globally. Currently, North America held largest market share due to higher rate of in-vitro diagnostics availability and technologically advanced medical devices which are primarily driving the market growth in North America. Asia Pacific is expected to show highest growth rate during forecast period due to the rising healthcare awareness, higher number of targeted population and increasing demand for advanced diagnostic technologies, fuelling the market growth during forecast period.

The global influenza market reached $5.1 billion in 2015. This market is expected to increase from $5.4 billion in 2016 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 3.6% for 2016-2021. Geographically, North America is the largest market for influenza vaccines capturing around 50% market share in 2016. Asia is the second largest market for influenza vaccines. Europe is the third largest market for influenza vaccines, followed by Latin America. Australasia accounted for least share of the influenza vaccines market in 2016.

According to market analysis, "Global Influenza Drugs and Vaccines Market - By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) - Analysis By Region, By Country: Opportunities and Forecast (2016-2021) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, U.K., Germany, France, China, India, Japan)", global market is projected to display a steady growth rate represented by a CAGR of 10.24% during 2017 - 2022, chiefly driven by increasing spending over various immunization programmes. In the influenza vaccines brand sales segment, Sanofi’s Fluzone holds the maximum share of the market being followed by Fluvirin/Flucelvax. GSK’s Fluarix/FluLaval accounts for the third highest share of the influenza vaccines market. Afluria/Fluvax and FluMist/Fluenz stands at the fourth and fifth position in the influenza vaccines market, while Flublok has captured least share of the influenza vaccines market. The global influenza vaccines market is anticipated to reach nearly US$ 5 Billion by 2022.

Market Competition Assessment

The influenza diagnostics market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Alere, Becton, Dickinson and Company, Meridian Bioscience, Inc., Princeton BioMedtech corp., Quidel Corporation, Roche Diagnostics, SA Scientific, Inc., Sekisui Diagnostics, Thermo Fisher Scientific and other.

Key Market Movements

  • Factors such as rising prevalence of influenza, upsurge funding by the government for diagnosis and treatment, growing demand for faster diagnosis and control of influenza are expected to drive the growth of influenza market during forecast period.
  • Vendors in the market are focusing on innovation and technological advances in developing ideal and cost effective diagnostic devices, this would further assist the growth of influenza diagnostics market globally.
  • However, some factors such as lower healthcare awareness in some countries may negatively impacting the growth of influenza diagnostics market globally.


A Symposium on Zika Virus

Orlando, USA, March 29, 2018

Allied Academies inviting the attendees who are in to research dealing with Zika virus from the fields of Microbiology, Virology, Pathology, Epidemiology, Immunology, NGO's and Clinicians. We would like to organize this session exclusively as a symposium apart from Influenza 2018, expecting huge number of research contributions towards this symposium on Zika Virus. It is an excellent opportunity to interact with the world class Scientists and it is the best platform to establish an international network.

Zika virus, first identified in 1947 in Uganda, had been thought to produce a rare and mild disease until it suddenly emerged in Brazil in 2015 and spread explosively through South America, Central America, and the Caribbean. The virus arrived in the United States in the summer of 2016. Zika virus is transmitted primarily by mosquitoes that thrive in tropical climates and urban areas. The virus can cause Zika virus disease. Zika virus can cause a serious birth defect known as microcephaly. Zika virus can also cause a neurologic condition in adults known as Guillain-Barre syndrome that results in muscle weakness or even paralysis in the worst cases. Two types of Aedes mosquitoes are capable of transmitting Zika virus – Aedes aegypti and Aedes albopictus. Aedes aegypti thought to be present only in 12 states in southern coastal areas of the United States, Aedes aegypti has now been found in about 30 states.

In Brazil, an explosive epidemic of a condition known as microcephaly has been correlated with the outbreak of Zika virus. Microcephaly can be caused by a number of genetic and environmental factors, including Down syndrome and fetal exposure to a variety of toxins. However, the number of microcephaly cases in Brazil since the Zika virus outbreak began is about twenty times higher than normally would be expected. It is estimated that approximately 500,000 cases of Zika virus infection have occurred in Brazil, although exact numbers are not known because of the difficulty in keeping track of the large number of cases and the fact that many infections go unnoticed. After Brazil, Columbia has been the most affected country with around 20,000 estimated cases. As of Oct. 26, 2016, there have been 139 laboratory confirmed cases acquired locally in Florida.

Zika Virus in the United States

As of Oct. 26, 2016, Zika virus infection has been acquired by nearly 4,000 people in the United States as a result of travel to areas where Zika virus infected mosquitoes are present. Travel-associated cases have been reported in all states except Alaska. The greatest number of cases is in New York and Florida with around 1,600 cases between them, followed by California and Texas. Of these cases, 33 were sexually transmitted. Approximately 950 pregnant women have laboratory evidence of Zika virus infection, and there have been more than 20 cases of birth defects or pregnancy losses tied to Zika infection.

  • Spread of Zika Virus
  • Zika Virus Complications
  • Transmission
  • Treatment and Prevention

To Collaborate Scientific Professionals around the World

Conference Date March 28-29, 2018
Speaker Oppurtunity Day 1 Day 2
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Join The Discussion

Mail us at

For Program Enquiry
More details about
Copyright © 2017-2018 Allied Academies, All Rights Reserved.